Bausch Health names Tom Vadaketh as future CFO, Sam Eldessouky to move to Bausch + Lomb

Bausch Health Companies Inc.

Sam Eldessouky will become CFO of Bausch + Lomb upon closing of its IPO.
Tom Vadaketh joins from eResearch Technology and will succeed Eldessouky as Bausch Health CFO at IPO close.
Vadaketh receives annual base salary of $600,000, target bonus of 60% of base, sign-on cash of $500,000, and equity grant of $3 million.
Employment agreement has initial three-year term with automatic one-year renewals.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sam Eldessouky

Chief Financial Officer

BHC · Bausch Health Companies Inc.

Successor: Tom Vadaketh
Filed: October 21, 2021, 7:59 PM ET

Sam Eldessouky, the current Chief Financial Officer of Bausch Health, will become Chief Financial Officer of Bausch + Lomb, effective as of the closing of the initial public offering of Bausch + Lomb

Appointed

Tom Vadaketh

Chief Financial Officer

BHC · Bausch Health Companies Inc.

Filed: October 21, 2021, 7:59 PM ET

On January 3, 2022, Tom Vadaketh will join Bausch Health from eResearch Technology Inc., and will serve as the Chief Financial Officer of the Company’s pharmaceutical business and, in connection with Mr. Eldessouky’s appointment as Chief Financial Officer of Bausch + Lomb at the time of the IPO, Mr. Vadaketh will be appointed as Chief Financial Officer of Bausch Health, effective as of the IPO Closing Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sam Eldessouky departed as Chief Financial Officer at Bausch Health Companies Inc..

Action: will become
Role: Chief Financial Officer

Exact text from the filing

Sam Eldessouky, the current Chief Financial Officer of Bausch Health, will become Chief Financial Officer of Bausch + Lomb, effective as of the closing of the initial public offering of Bausch + Lomb

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Tom Vadaketh was appointed as Chief Financial Officer at Bausch Health Companies Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 3, 2022, Tom Vadaketh will join Bausch Health from eResearch Technology Inc., and will serve as the Chief Financial Officer of the Company’s pharmaceutical business and, in connection with Mr. Eldessouky’s appointment as Chief Financial Officer of Bausch + Lomb at the time of the IPO, Mr. Vadaketh will be appointed as Chief Financial Officer of Bausch Health, effective as of the IPO Closing Date.

View on SEC.gov

Bausch Health Companies Inc. filing history →

Source: SEC EDGAR

accession 0000885590-21-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.